Goldman Sachs
VKTX icon

Goldman Sachs’s Viking Therapeutics VKTX Stock Holding History

Goldman Sachs’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-145,500
Closed -$5.12M – 7016
2025
Q4 		$5.12M Buy
145,500
+85,500
+143% +$3.03M ﹤0.01% 3726
2025
Q3 		$1.58M Sell
60,000
-30,000
-33% -$895K ﹤0.01% 4683
2025
Q2 		$2.38M Buy
90,000
+45,000
+100% +$1.18M ﹤0.01% 4042
2025
Q1 		$1.09M Buy
45,000
+35,000
+350% +$1.11M ﹤0.01% 4622
2024
Q4 		$402K Buy
+10,000
New +$570K ﹤0.01% 5358
2024
Q3 		– Sell
-128,300
Closed -$6.8M – 6088
2024
Q2 		$6.8M Buy
+128,300
New +$8.41M ﹤0.01% 2874
2023
Q2 		– Sell
-196,200
Closed -$3.27M – 6088
2023
Q1 		$3.27M Buy
+196,200
New +$2.03M ﹤0.01% 3449

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs's VKTX Position: Q2 2026 in Review

Goldman Sachs reduced its Viking Therapeutics (VKTX) stake by 1.8% in Q2 2026, selling an estimated $573K and leaving 942,841 shares worth $36.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

Goldman Sachs first reported a position in VKTX in Q2 2015 and has held it in 38 quarters since. The position peaked at $56.9M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Goldman Sachs held 942,841 shares of Viking Therapeutics worth $36.8M as of Q2 2026.
  • Goldman Sachs sold 17,729 Viking Therapeutics shares in Q2 2026, an estimated $573K.
  • Viking Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2074 holding.
  • Goldman Sachs first reported a position in Viking Therapeutics in Q2 2015 and has held it in 38 quarters since.
  • Goldman Sachs's Viking Therapeutics position peaked at $56.9M in Q2 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.